$84 Million

Cytovale Inc.

Series C Financing

Financial Advisor, November 2023

Cytovale Inc.

Cytovale is a medical diagnostics company focused on providing a more rapid and insightful way to diagnose fast-moving and immune-mediated diseases. The Company’s FDA-cleared rapid sepsis diagnosis test, IntelliSep, helps clinicians recognize sepsis and supports time-sensitive clinical decisions by providing test results in under 10 minutes. IntelliSep offers a new way of quickly and accurately analyzing white blood cells to assess a patient’s probability of sepsis from a standard blood draw — in August 2023, the Company announced the commercial launch of the IntelliSep test, following FDA 501(k) clearance in December 2022.

More Like This

Jan 2024
$250 Million

Follow-on Offering

Bookrunner

View Details >
Jan 2024
$113 Million

Follow-on Offering

Bookrunner

View Details >
Jan 2024

Frontier Service Partners, a portfolio company of Imperial Capital, has been acquired by Apex Service Partners, a platform of Alpine Investors

Exclusive Financial Advisor

View Details >